Grace Therapeutics, Inc.
GRCE Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$1.81
KIRA · Stoqly’s AI analyst, in plain words
- Grace Therapeutics, Inc. lost $7.8M in fiscal 2026.
Market cap
$31.3M
P/E
—
Revenue
—
Net income
−$7.8M
Free cash flow
—
Operating margin
—
Grace Therapeutics, Inc. in 30 seconds · fiscal 2026
Does it make a profit?
−$7.8M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Grace Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- March 31, 2026
- Latest annual report
- 10-K · Jun 18, 2026
- Legal name
- Grace Therapeutics, Inc.
- CIK
- 0001444192
Grace Therapeutics, Inc. · GRCE
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $100M | — | — | — | — |
| Revenue growth | 50,920.4% | — | — | — | — |
| Gross margin | 100.0% | — | — | — | — |
| Operating margin | −15.6% | — | — | — | — |
| Net income | −$9.8M | −$42.4M | −$12.9M | −$9.6M | −$7.8M |
| Net margin | −9.8% | — | — | — | — |
| Diluted EPS | −$0.27 | −$5.71 | −$1.35 | −$0.79 | −$0.47 |
| Cash | |||||
| Cash from operations | −$17.2M | −$15.9M | −$12.3M | −$14.9M | −$8.9M |
| Share count change | 148.5% | −79.8% | 28.2% | 26.8% | 36.6% |
| Debt and strength | |||||
| Cash and short-term investments | $43.7M | $27.9M | $23.0M | $22.1M | $17.0M |
| Shareholders' equity | $108M | $68.0M | $61.7M | $66.6M | $63.9M |
| Current ratio | 13.9x | 8.6x | 14.3x | 11.8x | 8.1x |
| Returns and quality | |||||
| Return on equity | −12.0% | −48.2% | −19.8% | −14.9% | −11.9% |
| Return on tangible equity | −38.5% | −227.0% | −103.0% | −55.2% | −53.3% |
| Piotroski F-score | 3 | — | — | — | — |
| Altman Z'' | 3.0 | −4.1 | −3.0 | 3.3 | 13.5 |
Insiders bought, 12 months
$0.8M
2 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Grace Therapeutics, Inc. · GRCE
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.81 a share, the company is worth $31.3M.
Source: SEC EDGAR XBRL filings (CIK 0001444192). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.